Global Critical Limb Ischemia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Critical Limb Ischemia treatment during 2019. Clinical development activities are being undertaken by more than 25 companies including Anaeropharma Science, Inc., AnGes MG Inc, Antidote Therapeutics Inc, Apceth Biopharma GmbH, Athersys, Inc. and others.
A Significant contribution to the Critical Limb Ischemia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Critical Limb Ischemia pipeline included 29 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Critical Limb Ischemia condition and increased access to investments is encouraging growth of Critical Limb Ischemia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Critical Limb Ischemia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Critical Limb Ischemia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Critical Limb Ischemia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Critical Limb Ischemia. Further, orphan drug status, fast track designation, grants awarded and other special status for Critical Limb Ischemia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Critical Limb Ischemia pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Critical Limb Ischemia Pipeline candidates-
A Significant contribution to the Critical Limb Ischemia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Critical Limb Ischemia pipeline included 29 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Critical Limb Ischemia condition and increased access to investments is encouraging growth of Critical Limb Ischemia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Critical Limb Ischemia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Critical Limb Ischemia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Critical Limb Ischemia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Critical Limb Ischemia. Further, orphan drug status, fast track designation, grants awarded and other special status for Critical Limb Ischemia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Critical Limb Ischemia pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Critical Limb Ischemia Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Critical Limb Ischemia drugs
- Late phase: Phase 3 and in-approval Critical Limb Ischemia drugs
- Company overview
- Snapshot
- Critical Limb Ischemia therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Critical Limb Ischemia- Disease Overview
2.2 Critical Limb Ischemia- Pipeline Snapshot
2.3 Critical Limb Ischemia- Pipeline Drugs by Phase
2.4 Critical Limb Ischemia- Pipeline Drugs by Company
2.5 Critical Limb Ischemia- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Anaeropharma Science, Inc. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.2 AnGes MG Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.3 Antidote Therapeutics Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.4 Apceth Biopharma GmbH Critical Limb Ischemia Drug Pipeline, H2- 2019
3.5 Athersys, Inc. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.6 BioGenCell Ltd. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.7 Biotech Holdings Critical Limb Ischemia Drug Pipeline, H2- 2019
3.8 Caladrius Biosciences, Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.9 Constant Pharmaceuticals LLC Critical Limb Ischemia Drug Pipeline, H2- 2019
3.10 Cynata Therapeutics Limited Critical Limb Ischemia Drug Pipeline, H2- 2019
3.11 Hemostemix Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.12 Histocell, S.L Critical Limb Ischemia Drug Pipeline, H2- 2019
3.13 ID Pharma Co., Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.14 Juventas Therapeutics, Inc. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.15 Kasiak Research Pvt. Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.16 LifeCells LLC Critical Limb Ischemia Drug Pipeline, H2- 2019
3.17 Neurofx Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.18 Pharmicell Co., Ltd. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.19 Pluristem Therapeutics Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.20 ReNeuron Group plc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.21 Reven Pharmaceuticals Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.22 Rexgenero Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.23 Symic Bio, Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.24 TaiGen Biotechnology Co Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.25 Taiwan Bio Therapeutics Co Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.26 TikoMed AB Critical Limb Ischemia Drug Pipeline, H2- 2019
3.27 U.S. Stem Cell Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.28 VESSL Therapeutics Ltd. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.29 ViroMed Co Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Critical Limb Ischemia- Phase 1 Drug Details
4.2 Critical Limb Ischemia- Phase 1 Drug Overview
4.3 Critical Limb Ischemia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Critical Limb Ischemia- Phase 2 Drug Details
5.2 Critical Limb Ischemia- Phase 2 Drug Overview
5.3 Critical Limb Ischemia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Critical Limb Ischemia- Phase 3 Drug Details
6.2 Critical Limb Ischemia- Phase 3 Drug Overview
6.3 Critical Limb Ischemia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Critical Limb Ischemia- Pre-clinical Phase Drug Details
7.2 Critical Limb Ischemia- Pre-clinical Phase Drug Overview
7.3 Critical Limb Ischemia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Critical Limb Ischemia- Disease Overview
2.2 Critical Limb Ischemia- Pipeline Snapshot
2.3 Critical Limb Ischemia- Pipeline Drugs by Phase
2.4 Critical Limb Ischemia- Pipeline Drugs by Company
2.5 Critical Limb Ischemia- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Anaeropharma Science, Inc. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.2 AnGes MG Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.3 Antidote Therapeutics Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.4 Apceth Biopharma GmbH Critical Limb Ischemia Drug Pipeline, H2- 2019
3.5 Athersys, Inc. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.6 BioGenCell Ltd. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.7 Biotech Holdings Critical Limb Ischemia Drug Pipeline, H2- 2019
3.8 Caladrius Biosciences, Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.9 Constant Pharmaceuticals LLC Critical Limb Ischemia Drug Pipeline, H2- 2019
3.10 Cynata Therapeutics Limited Critical Limb Ischemia Drug Pipeline, H2- 2019
3.11 Hemostemix Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.12 Histocell, S.L Critical Limb Ischemia Drug Pipeline, H2- 2019
3.13 ID Pharma Co., Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.14 Juventas Therapeutics, Inc. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.15 Kasiak Research Pvt. Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.16 LifeCells LLC Critical Limb Ischemia Drug Pipeline, H2- 2019
3.17 Neurofx Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.18 Pharmicell Co., Ltd. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.19 Pluristem Therapeutics Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.20 ReNeuron Group plc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.21 Reven Pharmaceuticals Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.22 Rexgenero Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.23 Symic Bio, Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.24 TaiGen Biotechnology Co Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.25 Taiwan Bio Therapeutics Co Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
3.26 TikoMed AB Critical Limb Ischemia Drug Pipeline, H2- 2019
3.27 U.S. Stem Cell Inc Critical Limb Ischemia Drug Pipeline, H2- 2019
3.28 VESSL Therapeutics Ltd. Critical Limb Ischemia Drug Pipeline, H2- 2019
3.29 ViroMed Co Ltd Critical Limb Ischemia Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Critical Limb Ischemia- Phase 1 Drug Details
4.2 Critical Limb Ischemia- Phase 1 Drug Overview
4.3 Critical Limb Ischemia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Critical Limb Ischemia- Phase 2 Drug Details
5.2 Critical Limb Ischemia- Phase 2 Drug Overview
5.3 Critical Limb Ischemia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Critical Limb Ischemia- Phase 3 Drug Details
6.2 Critical Limb Ischemia- Phase 3 Drug Overview
6.3 Critical Limb Ischemia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Critical Limb Ischemia- Pre-clinical Phase Drug Details
7.2 Critical Limb Ischemia- Pre-clinical Phase Drug Overview
7.3 Critical Limb Ischemia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
